Body Protection Compound 157 (BPC-157)
In short
15-amino acid peptide studied in animal models of angiogenesis and the repair of tendon and gastric tissues.
Overview
BPC-157 is a 15-amino-acid peptide isolated from a protective protein in gastric juice (Body Protection Compound). It is classified as a regenerative peptide and in the research literature is administered subcutaneously to study angiogenesis, tendon healing and gut tissue repair. The lyophilized material is reconstituted with bacteriostatic water before use.
Regenerative peptide that boosts VEGFR2 expression and stimulates fibroblasts to build type I and III collagen.
Molecular information
Amino-acid sequence
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
* 15-amino-acid fragment of a gastric juice protein; unusual stability in acidic environment
First-order decay curve at 6.0h half-life from literature. Educational only.
Research indications
Grouped by area. Each entry reflects a separate published hypothesis or clinical signal - not medical advice.
In the standard rat full-rupture model, BPC-157 raises VEGFR2 expression 3–5 fold and accelerates vascularization of the regenerating zone. Comparative histology shows denser collagen matrix at day 14 vs control (Chang et al., J Appl Physiol, 2014).
Injection-site reaction (redness, mild swelling)
common
Transient lethargy in first 1-2 days
uncommon
Mild nausea (oral administration)
uncommon
9 peer-reviewed sources
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
Chang et al. — Achilles tendon model
Animal study (rats) | 10 mcg/kg s.c. daily | 14 days | VEGFR2 expression 3-5x vs control group; significantly accelerated vascularization of regenerating tissue
J Appl Physiol · 2014
View the studySikiric et al. — NSAID-induced gastric lesions
Animal study (rats) | 10 mcg/kg s.c. | 5 days | Complete recovery from diclofenac-induced gastric ulcers via increased angiogenesis in submucosa
Curr Pharm Des · 2018
View the studySikiric et al. — Brain injury models
Animal study (rats) | 10 mcg/kg s.c. | Single and multiple dose protocols | Stabilization of dopaminergic axis after TBI; preserved eNOS activity in brain vasculature
Curr Pharm Des · 2014
View the studyHsieh et al. — Wound healing review
Review | Various (review) | Various (review) | Systematic review of angiogenic and collagen synthesis stimulation via FAK / paxillin / MAPK signaling pathways
Vascul Pharmacol · 2017
View the studyInformation about BPC-157 is based on published scientific research and is intended for research purposes only. Not medical advice.
Products are for in vitro laboratory research only. Not approved for human consumption.
Other peptides
5-Amino-1MQ
5-Amino-1MQ is a small-molecule selective inhibitor of NNMT (nicotinamide N-methyltransferase), identified by Anthony Sauve (Cornell) in 2018. NNMT is a "metabolic sink" for methyl donors and NAD+ — suppressing it in adipocytes raises energy expenditure without reducing calorie intake.
ReadAdipotide
Adipotide is a target peptide developed by Wadih Arap and Renata Pasqualini (MD Anderson) for selective elimination of white adipose tissue. It binds prohibitin on adipocyte vasculature and induces apoptosis of the blood vessels supplying fat tissue — leading to nonsurgical fat reduction.
ReadAOD-9604
AOD-9604 is a modified C-terminal 16-amino-acid fragment of human growth hormone (177-191), supplemented with a tyrosine residue. Retains the lipolytic effect of the full molecule but without diabetogenic or GH-stimulating activity. Developed by Metabolic Pharmaceuticals (Australia) in the 1990s.
ReadARA-290
ARA-290 (Cibinetide) is an 11-amino-acid fragment of erythropoietin (EPO) developed by Anthony Cerami as a cytoprotective molecule without erythropoietic activity. It retains the tissue-protective effects of EPO without raising hematocrit — explaining its potential in diabetic neuropathy and cardiac applications.
ReadArgireline
Argireline is a synthetic acetylated hexapeptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2) derived from SNAP-25 — the SNARE complex subunit mediating acetylcholine release at neuromuscular junctions. Topical application reduces muscle activity in expression areas — which is why Argireline is marketed as a "topical Botox alternative".
ReadCagrilintide
Cagrilintide is a modified amylin analog developed by Novo Nordisk as a partner to semaglutide in combined incretin-amylin therapy. CagriSema (cagrilintide + semaglutide) showed 17.1% body-weight reduction in Phase 2 — a promising next step over semaglutide alone.
ReadEducation
No comments yet. Be the first.
Comments are reviewed before publishing.
